Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Registration Number
- NCT00649389
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
-
Demonstrable hypertension defined as mean sitting trough cuff blood pressure ≥ 140/100 mmHg (SeSBP ≥ 140 mmHg and SeDBP ≥ 100mmHg) or mean sitting trough cuff BP ≥ 160/90 mmHg (SeSBP ≥ 160 mmHg and SeDBP ≥ 90mmHg).
-
Male or female newly diagnosed hypertensive subjects or currently on hypertension medication.
-
Negative urine pregnancy test at screening
-
Not lactating
-
Do not plan to become pregnant during the study
-
Will practice birth control throughout the study by the following: oral or patch contraceptive, injectable or implantable contraceptive medication, intrauterine device, diaphragm or female condom plus spermicide
- Non childbearing potential must be classified by one of the following criteria
- Had a hysterectomy or tubal ligation at least 6 months prior to consent
- Has been postmenopausal for a least 1 year
-
Exclusion Criteria
- Mean sitting trough cuff DBP <90 mmHg or mean sitting trough cuff SBP <140 mmHg (off antihypertensive medication).
- Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at the discretion of the investigator).
- Signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion.
- History of hypertensive encephalopathy, stroke or transient ischemic attack (TIA).
- Participation in another clinical trial involving an investigational drug within one month prior to screening.
- History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina within the past 6 months.
- Any history of New York Heart Association Class III or IV congestive heart failure (CHF). A history of New York Heart Association Class I or II CHF may be exclusionary at the discretion of the investigator.
- History of secondary hypertension including renal disease, pheochromocytoma, or Cushing's syndrome.
- Uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a solitary kidney.
- Evidence of symptomatic resting bradycardia.
- Evidence of hemodynamically significant cardiac valvular disease.
- Presence of heart block greater than first degree atrioventricular block, chronic atrial fibrillation or flutter.
- Uncontrolled Type I or Type II diabetes defined as HbA1c >9.0%. Diabetics must have documentation of HbA1c within 6 months of the Screening Visit. Undocumented subjects must have their HbA1c assessed prior to randomization. Note: Subjects with Type I or Type II diabetes controlled with insulin, diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included.
- Evidence of liver disease as indicated by ALT and AST and/or total bilirubin >3 times the upper limit of normal.
- Severe renal insufficiency defined as a creatinine clearance (based on the Cockcroft-Gault formula) of <30 mL/min.
- Clinically significant laboratory elevations at Visit 1 that compromise subject safety, based on the investigator's judgment. Consideration should take into account the potential laboratory effects of the component blinded therapies.
- Positive for any one of the following tests: hepatitis B surface antigen, hepatitis C antibody (confirmed by radio immunobinding assay, RIBA) or HIV antibody (confirmed by western blot assay).
- Subjects with malignancy during the past 2 years excluding squamous cell or basal cell carcinoma of the skin.
- Known allergy to any of the medications used in the study.
- Subjects who require or are taking any concomitant medication, which may interfere with the objectives of the study (Refer to Section 5.2 for a listing of excluded medications).
- Pregnant or lactating females.
- Current history of drug or alcohol abuse.
- A subject with any medical condition, which in the judgment of the Investigator would jeopardize the evaluation of efficacy or safety and/or constitute a significant safety risk to the subject.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description OM40/AML10 Olmesartan medoxomil olmesartan medoxomil 40mg and amlodipine 10mg OM40/AML10 Amlodipine olmesartan medoxomil 40mg and amlodipine 10mg OM40/HCTZ25 Hydrochlorothiazide olmesartan medoxomil 40mg and hydrochlorothiazide 25mg OM40/HCTZ25 Olmesartan medoxomil olmesartan medoxomil 40mg and hydrochlorothiazide 25mg OM40/AML10/HCTZ25 Hydrochlorothiazide olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg OM40/AML10/HCTZ25 Olmesartan medoxomil olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg AML10/HCTZ25 Amlodipine amlodipine 10mg and hydrochlorothiazide 25mg OM40/AML10/HCTZ25 Amlodipine olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg AML10/HCTZ25 Hydrochlorothiazide amlodipine 10mg and hydrochlorothiazide 25mg
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP). baseline to 12 weeks
- Secondary Outcome Measures
Name Time Method Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination Baseline to 12 weeks or early termination Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks Baseline to 12 weeks Change in Seated Systolic Blood Pressure From Baseline to Week 12 Baseline to week 12